Price History
Feb 9, 2026 — Mar 27, 2026Investment Snapshot
- Trading 96% below Graham Number ($30.90) — significant margin of safety
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 63.9% — good return on equity
Enlivex Ltd. - Ordinary Shares (ENLV) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $259 million . Key value metrics: P/E ratio 0.2, P/B ratio 0.13, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Enlivex Ltd. - Ordinary Shares — Fundamental Analysis Summary
Enlivex Ltd. - Ordinary Shares (ENLV) is trading 96% below its Graham Number of $30.90 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 0.2x.
On financial health, ENLV shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and strong return on equity of 63.9% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.02.
StockPik's composite Value Score for ENLV is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ENLV shows earnings growing at 8,329%.